

Andreas Jung

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/129639/publications.pdf>

Version: 2024-02-01

73
papers

3,140
citations

304743

22
h-index

155660

55
g-index

74
all docs

74
docs citations

74
times ranked

5244
citing authors

#	ARTICLE	IF	CITATIONS
1	Disease Modeling on Tumor Organoids Implicates AURKA as a Therapeutic Target in Liver Metastatic Colorectal Cancer. Cellular and Molecular Gastroenterology and Hepatology, 2022, 13, 517-540.	4.5	11
2	BRAF-mutant metastatic colorectal cancer: Prognostic and predictive value of primary tumor locationâ€”A pooled analysis of the AIO studies FIRE-1, CIOX, XELAVIRI, FIRE-3, and VOLFI.. Journal of Clinical Oncology, 2022, 40, 3576-3576.	1.6	2
3	FOLFIRI plus cetuximab or bevacizumab for advanced colorectal cancer: final survival and per-protocol analysis of FIRE-3, a randomised clinical trial. British Journal of Cancer, 2021, 124, 587-594.	6.4	79
4	Mixed large cell neuroendocrine carcinoma and squamous cell carcinoma of the colon: detailed molecular characterisation of two cases indicates a distinct colorectal cancer entity. Journal of Pathology: Clinical Research, 2021, 7, 75-85.	3.0	4
5	Detection of gene fusions using targeted next-generation sequencing: a comparative evaluation. BMC Medical Genomics, 2021, 14, 62.	1.5	58
6	Routine application of next-generation sequencing testing in uro-oncologyâ€”Are we ready for the next step of personalised medicine?. European Journal of Cancer, 2021, 146, 1-10.	2.8	5
7	FOLFOX plus panitumumab or FOLFOX alone as additive therapy following R0/1 resection of RAS wild-type colorectal cancer liver metastases: The PARLIM trial (AIO KKR 0314).. Journal of Clinical Oncology, 2021, 39, 3553-3553.	1.6	0
8	Consensus molecular subtypes and <i>RAS</i> status as biomarker of treatment intensity with fluoropyrimidine, bevacizumab, and irinotecan in metastatic colorectal cancer (XELAVIRI, AIO KKR) Tj ETQq0 0 0 rgBTd/Overlock 10 Tf 50		
9	Prognostic and predictive value of PD-L1 expression and tumour infiltrating lymphocytes (TILs) in locally advanced NSCLC treated with simultaneous radiochemotherapy in the randomized, multicenter, phase III German Intergroup lung Trial (GILT). Lung Cancer, 2021, 160, 17-27.	2.0	10
10	Consensus molecular subtypes in metastatic colorectal cancer treated with sequential versus combined fluoropyrimidine, bevacizumab and irinotecan (XELAVIRI trial). European Journal of Cancer, 2021, 157, 71-80.	2.8	4
11	p130Cas Is Correlated with EREG Expression and a Prognostic Factor Depending on Colorectal Cancer Stage and Localization Reducing FOLFIRI Efficacy. International Journal of Molecular Sciences, 2021, 22, 12364.	4.1	3
12	Therapeutic management of neuro-oncologic patients - potential relevance of CSF liquid biopsy. Theranostics, 2020, 10, 856-866.	10.0	25
13	Impact of age on efficacy and early mortality of initial sequential treatment versus upfront combination chemotherapy in patients with metastatic colorectal cancer: a subgroup analysis of a phase III trial (AIO KKR0110, XELAVIRI study). European Journal of Cancer, 2020, 137, 81-92.	2.8	3
14	Single-nucleotide variants, tumour mutational burden and microsatellite instability in patients with metastatic colorectal cancer: Next-generation sequencing results of the FIRE-3 trial. European Journal of Cancer, 2020, 137, 250-259.	2.8	15
15	Amphiregulin Expression Is a Predictive Biomarker for <i>EGFR</i> Inhibition in Metastatic Colorectal Cancer: Combined Analysis of Three Randomized Trials. Clinical Cancer Research, 2020, 26, 6559-6567.	7.0	17
16	Predictive and prognostic value of magnesium serum level in FOLFIRI plus cetuximab or bevacizumab treated patients with stage IV colorectal cancer: results from the FIRE-3 (AIO KKR-0306) study. Anti-Cancer Drugs, 2020, 31, 856-865.	1.4	2
17	Prognostic importance of primary tumor resection and synchronous metastasis on overall survival in metastatic colorectal cancer: Data from the FIRE-3 (AIO KKR-0306) study.. Journal of Clinical Oncology, 2020, 38, 4070-4070.	1.6	0
18	Validation of miR-31-3p Expression to Predict Cetuximab Efficacy When Used as First-Line Treatment in <i>RAS</i> Wild-Type Metastatic Colorectal Cancer. Clinical Cancer Research, 2019, 25, 134-141.	7.0	34

#	ARTICLE	IF	CITATIONS
19	Lymph node infiltration, parallel metastasis and treatment success in breast cancer. <i>Breast</i> , 2019, 48, 1-6.	2.2	16
20	The Evolving Biomarker Landscape for Treatment Selection in Metastatic Colorectal Cancer. <i>Drugs</i> , 2019, 79, 1375-1394.	10.9	48
21	RBP7 is a clinically prognostic biomarker and linked to tumor invasion and EMT in colon cancer. <i>Journal of Cancer</i> , 2019, 10, 4883-4891.	2.5	20
22	Association of microRNA-21 with efficacy of cetuximab in RAS wild-type patients in the FIRE-3 study (AIO Tj ETQq0 0 0 rgBT /Overlock 1 Clinical Oncology, 2019, 37, 3593-3593.	1.6	4
23	Gender and survival benefit from initial irinotecan in metastatic colorectal cancer: Analysis of the XELAVIRI (AIOKRK0110) study.. <i>Journal of Clinical Oncology</i> , 2019, 37, 549-549.	1.6	1
24	Effect of patient age on efficacy of FOLFIRI plus cetuximab vs bevacizumab in 1st-line treatment of metastatic colorectal cancer: An analysis of FIRE-3 (AIO KRK 0306).. <i>Journal of Clinical Oncology</i> , 2019, 37, 3541-3541.	1.6	0
25	Association of MAPK signaling subtypes with prognostic benefit for bevacizumab in left-sided metastatic colorectal cancer (mCRC) patients treated with FOLFIRI + cetuximab / bevacizumab (FIRE-3) Tj ETQq1 1 07843140rgBT /Over		
26	Concurrent radiotherapy and nivolumab in metachronous metastatic primary adenosquamous-cell carcinoma of the prostate. <i>European Journal of Cancer</i> , 2018, 95, 109-111.	2.8	5
27	Opposing Effects of CREBBP Mutations Govern the Phenotype of Rubinstein-Taybi Syndrome and Adult SHH Medulloblastoma. <i>Developmental Cell</i> , 2018, 44, 709-724.e6.	7.0	35
28	Relevance of liver-limited disease in metastatic colorectal cancer: Subgroup findings of the FIRE-3/AIO KRK0306 trial. <i>International Journal of Cancer</i> , 2018, 142, 1047-1055.	5.1	12
29	Amphiregulin (AREG) and Epiregulin (EREG) Gene Expression as Predictor for Overall Survival (OS) in Oxaliplatin/Fluoropyrimidine Plus Bevacizumab Treated mCRC Patients-Analysis of the Phase III AIO KRK-0207 Trial. <i>Frontiers in Oncology</i> , 2018, 8, 474.	2.8	13
30	The DNA-polymorphism rs849142 is associated with skin toxicity induced by targeted anti-EGFR therapy using cetuximab. <i>Oncotarget</i> , 2018, 9, 30279-30288.	1.8	6
31	POLE gene hotspot mutations in advanced pancreatic cancer. <i>Journal of Cancer Research and Clinical Oncology</i> , 2018, 144, 2161-2166.	2.5	15
32	Targeting tumor cell plasticity by combined inhibition of NOTCH and MAPK signaling in colon cancer. <i>Journal of Experimental Medicine</i> , 2018, 215, 1693-1708.	8.5	31
33	Somatic DNA mutations, tumor mutational burden (TMB), and MSI Status: Association with efficacy in patients (pts) with metastatic colorectal cancer (mCRC) of FIRE-3 (AIO KRK-0306).. <i>Journal of Clinical Oncology</i> , 2018, 36, 3591-3591.	1.6	12
34	Per protocol analysis and final OS update of the FIRE-3 (AIO KRK-0306) study comparing FOLFIRI plus cetuximab vs. FOLFIRI plus bevacizumab.. <i>Journal of Clinical Oncology</i> , 2018, 36, 3508-3508.	1.6	0
35	Oncogenic Effects of High MAPK Activity in Colorectal Cancer Mark Progenitor Cells and Persist Irrespective of RAS Mutations. <i>Cancer Research</i> , 2017, 77, 1763-1774.	0.9	58
36	Extended RAS analysis and correlation with overall survival in advanced pancreatic cancer. <i>British Journal of Cancer</i> , 2017, 116, 1462-1469.	6.4	25

#	ARTICLE	IF	CITATIONS
37	Universal Genomic Testing: The next step in oncological decision-making or a dead end street?. European Journal of Cancer, 2017, 82, 72-79.	2.8	13
38	The Munich MIDY Pig Biobank – A unique resource for studying organ crosstalk in diabetes. Molecular Metabolism, 2017, 6, 931-940.	6.5	39
39	Switch in KRAS mutational status during an unusual course of disease in a patient with advanced pancreatic adenocarcinoma: implications for translational research. BMC Cancer, 2017, 17, 374.	2.6	1
40	Prognostic significance of BRAF and NRAS mutations in melanoma: a German study from routine care. BMC Cancer, 2017, 17, 536.	2.6	113
41	Consensus molecular subgroups (CMS) of colorectal cancer (CRC) and first-line efficacy of FOLFIRI plus cetuximab or bevacizumab in the FIRE3 (AIO KRK-0306) trial.. Journal of Clinical Oncology, 2017, 35, 3510-3510.	1.6	34
42	Primary tumor location and efficacy of second-line therapy after initial treatment with FOLFIRI in combination with cetuximab or bevacizumab in patients with metastatic colorectal cancer- FIRE-3 (AIOKRK0306).. Journal of Clinical Oncology, 2017, 35, 3525-3525.	1.6	7
43	FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab for metastatic colorectal cancer (FIRE-3): a post-hoc analysis of tumour dynamics in the final RAS wild-type subgroup of this randomised open-label phase 3 trial. Lancet Oncology, The, 2016, 17, 1426-1434.	10.7	336
44	RAS testing in metastatic colorectal cancer: advances in Europe. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2016, 468, 383-396.	2.8	27
45	Differences in gene-expression in mCRC tissue samples with regard to tumor location and used chemotherapeutic substances: Data of the FIRE-1 study.. Journal of Clinical Oncology, 2016, 34, 562-562.	1.6	0
46	Time-course evaluation of survival and treatment in FIRE-3 (AIO KRK0306, first-line therapy of KRAS) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 5 Clinical Oncology, 2016, 34, 617-617.	1.6	0
47	Influence of mRNA expression of fibroblast growth factor 2 (FGF2) in colorectal cancer (CRC) cell lines and in patients with metastatic colorectal cancer (mCRC) treated with FOLFIRI or mlrX (FIRE1).. Journal of Clinical Oncology, 2016, 34, 3570-3570.	1.6	0
48	Influence of KRAS exon 2 mutation variants as well as NRAS- and BRAF-mutations on outcome of patients with metastatic colorectal cancer (mCRC) receiving combination chemotherapy with or without bevacizumab.. Journal of Clinical Oncology, 2016, 34, 3551-3551.	1.6	0
49	Expression of cancer stem cell markers in metastatic colorectal cancer correlates with liver metastasis, but not with metastasis to the central nervous system. Pathology Research and Practice, 2015, 211, 601-609.	2.3	31
50	Polymorphisms in Genes Involved in EGFR Turnover Are Predictive for Cetuximab Efficacy in Colorectal Cancer. Molecular Cancer Therapeutics, 2015, 14, 2374-2381.	4.1	4
51	GATA2 deficiency in children and adults with severe pulmonary alveolar proteinosis and hematologic disorders. BMC Pulmonary Medicine, 2015, 15, 87.	2.0	63
52	The E3 ligase RNF43 inhibits Wnt signaling downstream of mutated β -catenin by sequestering TCF4 to the nuclear membrane. Science Signaling, 2015, 8, ra90.	3.6	67
53	Impact of Subsequent Therapies on Outcome of the FIRE-3/AIO KRK0306 Trial: First-Line Therapy With FOLFIRI Plus Cetuximab or Bevacizumab in Patients With KRAS Wild-Type Tumors in Metastatic Colorectal Cancer. Journal of Clinical Oncology, 2015, 33, 3718-3726.	1.6	112
54	Influence of adjuvant pretreatment on outcome of FIRE-3 (AIO KRK-0306): A randomized phase III study of FOLFIRI plus cetuximab or bevacizumab as first-line treatment for wild-type (WT) KRAS (exon 2) metastatic colorectal cancer (mCRC) patients.. Journal of Clinical Oncology, 2015, 33, 515-515.	1.6	1

#	ARTICLE	IF	CITATIONS
55	Cetuximab-induced skin rash: A molecular map relating polymorphisms, cell-adhesion, and autoimmunity.. Journal of Clinical Oncology, 2015, 33, 570-570.	1.6	1
56	Treatment until progression: Data of the "œon-treatment" population of the FIRE-3 (AIO KRK-0306) study.. Journal of Clinical Oncology, 2015, 33, 3589-3589.	1.6	0
57	Baseline carcinoembryonic antigen (CEA) serum levels to predict bevacizumab-based treatment response in patients with KRAS exon wild-type metastatic colorectal cancer (mCRC) receiving 1st-line therapy with FOLFIRI plus cetuximab or bevacizumab (AIO KRK0306, FIRE3 trial).. Journal of Clinical Oncology, 2015, 33, 3581-3581.	1.6	0
58	Prevalence and influence on outcome of Neuregulin- (NRG1), HER2/neu- and HER3- expression in patients with metastatic colorectal cancer (mCRC) treated with irinotecan-based first-line regimens (FUFIRI vs. mIROX) in the FIRE 1-trial.. Journal of Clinical Oncology, 2015, 33, e14609-e14609.	1.6	0
59	Disease kinetics but not disease burden is relevant for survival in melanoma of unknown primary tumor. Discovery Medicine, 2015, 20, 231-7.	0.5	3
60	Colorectal Cancers Mimic Structural Organization of Normal Colonic Crypts. PLoS ONE, 2014, 9, e104284.	2.5	21
61	Dedifferentiated chondrosarcoma mimicking a giant cell tumor. Is this low grade dedifferentiated chondrosarcoma?. Pathology Research and Practice, 2014, 210, 194-197.	2.3	8
62	Oxyphil Cell Metaplasia in the Parathyroids Is Characterized by Somatic Mitochondrial DNA Mutations in NADH Dehydrogenase Genes and Cytochrome c Oxidase Activity" Impairing Genes. American Journal of Pathology, 2014, 184, 2922-2935.	3.8	16
63	FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): a randomised, open-label, phase 3 trial. Lancet Oncology, The, 2014, 15, 1065-1075.	10.7	1,479
64	Amphiregulin (AREG) SNP rs161511 to predict cetuximab efficacy independent of AREG mRNA levels: Data from FIRE3 (AIO KRK-0306).. Journal of Clinical Oncology, 2014, 32, 3521-3521.	1.6	1
65	Second-line therapies in patients with KRAS wild-type metastatic colorectal cancer (mCRC) after first-line therapy with FOLFIRI in combination with cetuximab or bevacizumab in the AIO KRK0306 (FIRE) Tj ETQq1 1.0.784314 rgBT /Ove	1.6	1
66	Gender and tumor location as predictors for efficacy: Influence on endpoints in first-line treatment with FOLFIRI in combination with cetuximab or bevacizumab in the AIO KRK 0306 (FIRE3) trial.. Journal of Clinical Oncology, 2014, 32, 3600-3600.	1.6	51
67	Epithelial-Mesenchymal Transition Induces Endoplasmic-Reticulum-Stress Response in Human Colorectal Tumor Cells. PLoS ONE, 2014, 9, e87386.	2.5	21
68	Influence of mRNA expression of epiregulin (EREG) and of amphiregulin (AREG) and RAS mutationson outcome of patients with metastatic colorectal cancer treated with 5-FU/LV plus irinotecan or irinotecan plus oxaliplatin as first-line treatment (FIRE 1-trial).. Journal of Clinical Oncology, 2014, 32, 3522-3522.	1.6	1
69	Randomized comparison of FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment of KRAS wild-type metastatic colorectal cancer: German AIO study KRK-0306 (FIRE-3).. Journal of Clinical Oncology, 2013, 31, LBA3506-LBA3506.	1.6	49
70	Phosphorylated ERK (pERK) as biomarker in patients with advanced pancreatic cancer treated with erlotinib within a randomized phase III trial (AIO-PK0104).. Journal of Clinical Oncology, 2013, 31, 189-189.	1.6	0
71	Randomized comparison of FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment of KRAS-wildtype metastatic colorectal cancer: German AIO study KRK-0306 (FIRE-3).. Journal of Clinical Oncology, 2013, 31, LBA3506-LBA3506.	1.6	21
72	Ligand expression of the EGFR ligands amphiregulin, epiregulin, and amplification of the EGFR gene to predict for treatment efficacy in KRAS wild-type mCRC patients treated with cetuximab plus CAPIRI and CAPOX: Analysis of the randomized AIO CRC-0104 trial.. Journal of Clinical Oncology, 2012, 30, 3519-3519.	1.6	6

#	ARTICLE	IF	CITATIONS
73	Orbital Rhabdomyosarcoma in Noonan Syndrome. Journal of Pediatric Hematology/Oncology, 2003, 25, 330-332.	0.6	35